In a bid to bolster its preclinical pipeline, Novartis has entered into a licensing agreement with MorphoSys for US$23 M. Through the deal, Novartis will be granted a global license to MorphoSys’ preclinical inhibitors of a new cancer target. Interestingly, the deal comes six months after MorphoSys outlicensed two of its antibody therapies, felzartamaband MOR210, to Human Immunology Biosciences as it looked to refocus its pipeline on oncology.